University of Bordeaux Reports Findings in Antidiabetic Agents (Use of sodium-glucose cotransporter-2 inhibitors in France: Analysis of French nationwide health insurance database): Drugs and Therapies – Antidiabetic Agents

2024 FEB 14 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- New research on Drugs and Therapies - Antidiabetic Agents is the subject of a report. According to news reporting originating in Bordeaux, France, by NewsRx journalists, research stated, “Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) have been commercialized in France for type 2 diabetes since April 2020 and later for heart and renal diseases. Given the recent developments in treating diabetes and the widening of SGLT-2i indications, we aimed to study changes in the use of glucose-lowering drugs in France and to characterize SGLT-2i new users.”

Financial support for this research came from Agence Nationale de Securite du Medicament et des Produits de Sante.

The news reporters obtained a quote from the research from the University of Bordeaux, “We performed a nationwide utilization study using the French health insurance database. Trends in incidence and prevalence of glucose-lowering drug use were assessed by a repeated cross-sectional study in 2019 and 2021. A cohort study of incident SGLT-2i users was then conducted to describe patient characteristics and the strategy for treating diabetes. The prevalence of SGLT-2i use gradually reached 0.1% in the third quarter of 2021 and increased more significantly to 0.2% thereafter. SGLT-2i became the second most prescribed glucose-lowering drug class after metformin at the end of 2021 (0.1%). Among the cohort of 125 387 SGLT-2i new users (mean age 65.0 years; 60.1% of men), 87.6% presented a diabetic comorbidity. The patient profile changed over the study period with an increasing proportion of patients with cardiovascular (28.7% in 2020 vs. 40.2% in 2021) or renal (7.7% in 2020 vs. 11.8% in 2021) comorbidities at initiation. The main combinations used at SGLT-2i initiation were metformin (12.5%) and metformin plus dipeptidyl peptidase-4 inhibitors (8.1%). One-year probability of SGLT-2i persistence was estimated to be 55%.”

According to the news reporters, the research concluded: “The expansion of indications for SGLT-2i and the broadening of the target population make it essential to assess the reasons for discontinuation and review their safety profile.”

This research has been peer-reviewed.

For more information on this research see: Use of sodium-glucose cotransporter-2 inhibitors in France: Analysis of French nationwide health insurance database. Diabetes, Obesity and Metabolism, 2024. Diabetes, Obesity and Metabolism can be contacted at: Wiley, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - http://www.wiley.com/; Diabetes, Obesity and Metabolism - http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1463-1326)

Our news correspondents report that additional information may be obtained by contacting Elodie Pambrun, University of Bordeaux, French National Institute of Health and Medical Research (INSERM), BPH, U1219 Team AHeaD, Bordeaux, France. Additional authors for this research include Sibylle de Germay, Antoine Pariente, Guillaume Grenet, Julien Bezin and Jean-Luc Faillie.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1111/dom.15472. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

The publisher of the journal Diabetes, Obesity and Metabolism can be contacted at: Wiley, 111 River St, Hoboken 07030-5774, NJ, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)